Israeli-based RedHill Biopharma has signed a co-promotion agreement with Canadian-based Concordia International’s subsidiary to acquire certain US promotion rights for the prescription oral drug Donnatal that is used with other drugs to treat irritable bowel syndrome (IBS).
IBS is a chronic multifactorial disorder characterised by recurrent abdominal pain or discomfort associated with altered bowel function.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
As per the agreement terms, RedHill will be responsible for certain promotional activities related to the drug, while Concordia will take responsbility for its manufacturing and supply in all territories.
RedHill CEO Dror Ben-Asher said: “With a core US commercial team in place, we plan to initiate promotional activities in the US in the coming months with a specialty gastrointestinal sales force.
“RedHill’s strategic transition into a revenue-generating, gastrointestinal-focused, specialty pharmaceutical company with commercial presence in the US, is planned to support potential future commercialisation of our Phase III-stage potential blockbusters Bekinda for gastroenteritis and other GI indications, RHB-105 for H. pylori infection and RHB-104 for Crohn’s disease, if approved by FDA.”
Based on an agreed upon split, RedHill and Concordia will share the revenues generated from the promotion of the drug.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataThe agreement with Concordia is initially for a period of three years.
Concordia CEO Allan Oberman said: “This agreement is a cost-effective approach to promoting Donnatal in a manner consistent with our long-term strategic focus on operational excellence.
“We look forward to partnering with them to market Donnatal to more key prescribers who we believe can help raise the product’s profile and potentially allow us to reach more patients in the US.”
Donnatal relaxes the muscles in the stomach and intestines and acts on the brain to produce a calming effect and slows the natural movements of the gut.
It is available in two formulations: immediate release Donnatal Tablets, and immediate release Donnatal Elixir, a fast acting liquid.
